CU20200040A7 - Profármacos de derivados de triazol sustituido - Google Patents

Profármacos de derivados de triazol sustituido

Info

Publication number
CU20200040A7
CU20200040A7 CU2020000040A CU20200040A CU20200040A7 CU 20200040 A7 CU20200040 A7 CU 20200040A7 CU 2020000040 A CU2020000040 A CU 2020000040A CU 20200040 A CU20200040 A CU 20200040A CU 20200040 A7 CU20200040 A7 CU 20200040A7
Authority
CU
Cuba
Prior art keywords
propharmacs
triazole derivatives
substituted triazole
triazol
carboxamide
Prior art date
Application number
CU2020000040A
Other languages
English (en)
Other versions
CU24604B1 (es
Inventor
Dr Anja Buchmueller
Dr Hana Cernecka
Dr Marie-Pierre Collin-Kroepelin
Dr Karoline Droebner
Dr Robert Fricke
Dr Chantal Fuerstner
Dr Peter Kolkhof
Ursula Krenz
Dr Axel Kretschmer
Dr Guillaume Levilain
Dr Klemens Lustig
Dr Thomas Mondritzki
Dr Thomas Neubauer
Dr Elisabeth Pook
Dr Heiko Schirmer
Dr Carsten Schmeck
Dr Hanna Tinel
Dr Pierre Wasnaire
Dr Norbert Witowski
Dr Matthias Beat Wittwer
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20200040A7 publication Critical patent/CU20200040A7/es
Publication of CU24604B1 publication Critical patent/CU24604B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere a profármacos 3-({ 3-(4-clorofenil)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hidroxipropil]-4,5-dihidro-1H-1,2,4-triazol-1-il} metil)-1-[3-(trifluorometil)-piridin-2-2-il]-1H-1,2,4-triazol-5-carboxamida, 3-({3-(4-clorofenil)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hidroxipropil]-4,5-dihidro-1H-1,2,4-triazol-1-il} metil)-1-[2-(trifluorometil)-fenil]-1H-1,2,4-triazol-5-carboxamida y 3-({ 3-(4-clorofenil)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hidroxipropil]-4,5-dihidro-1H-1,2,4-triazol-1-il} metil)-1-(cloropiridin-2-il)-1H-1,2,4-triazol-5-carboxamida, útiles en el tratamiento de enfermedades renales y cardiovasculares.</p>
CU2020000040A 2017-10-24 2018-10-17 Profármacos de derivados de triazol sustituido CU24604B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197935 2017-10-24
PCT/EP2018/078364 WO2019081292A1 (en) 2017-10-24 2018-10-17 PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF

Publications (2)

Publication Number Publication Date
CU20200040A7 true CU20200040A7 (es) 2021-03-11
CU24604B1 CU24604B1 (es) 2022-06-06

Family

ID=60162099

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000040A CU24604B1 (es) 2017-10-24 2018-10-17 Profármacos de derivados de triazol sustituido

Country Status (38)

Country Link
US (1) US11298367B2 (es)
EP (1) EP3700913B1 (es)
JP (1) JP2021500365A (es)
KR (1) KR20200069361A (es)
CN (1) CN111225921A (es)
AR (1) AR113791A1 (es)
AU (1) AU2018356352A1 (es)
BR (1) BR112020007983A2 (es)
CA (1) CA3079767A1 (es)
CL (1) CL2020001076A1 (es)
CO (1) CO2020004945A2 (es)
CR (1) CR20200176A (es)
CU (1) CU24604B1 (es)
CY (1) CY1124938T1 (es)
DK (1) DK3700913T3 (es)
DO (1) DOP2020000076A (es)
EA (1) EA202091025A1 (es)
EC (1) ECSP20023056A (es)
ES (1) ES2906305T3 (es)
HR (1) HRP20220060T1 (es)
HU (1) HUE057278T2 (es)
IL (1) IL273949A (es)
JO (1) JOP20200099A1 (es)
LT (1) LT3700913T (es)
MA (1) MA50438B1 (es)
MX (1) MX2020004191A (es)
NI (1) NI202000030A (es)
PE (1) PE20210394A1 (es)
PH (1) PH12020550473A1 (es)
PL (1) PL3700913T3 (es)
PT (1) PT3700913T (es)
RS (1) RS62984B1 (es)
SG (1) SG11202003049WA (es)
SI (1) SI3700913T1 (es)
TW (1) TW201932117A (es)
UA (1) UA126456C2 (es)
UY (1) UY37948A (es)
WO (1) WO2019081292A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
BRPI0417267A (pt) 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
CA2703996A1 (en) * 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AR076542A1 (es) * 2009-05-22 2011-06-22 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
PL2539326T3 (pl) 2010-02-27 2017-10-31 Bayer Ip Gmbh Połączone bis-arylem arylotriazolony i ich zastosowanie
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2804470A1 (en) 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015055707A1 (en) * 2013-10-16 2015-04-23 Bayer Cropscience Ag Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound
KR20170081178A (ko) 2014-11-03 2017-07-11 바이엘 파마 악티엔게젤샤프트 히드록시알킬-치환된 페닐트리아졸 유도체 및 그의 용도
UY36571A (es) * 2015-03-05 2016-09-30 Bayer Cropscience Ag Combinaciones de compuestos activos
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
AR108263A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
JP6911052B2 (ja) 2016-05-03 2021-07-28 バイエル ファーマ アクチエンゲゼルシャフト オキソアルキル置換フェニルトリアゾール誘導体およびその使用
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2018073144A1 (en) 2016-10-20 2018-04-26 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof

Also Published As

Publication number Publication date
CN111225921A (zh) 2020-06-02
CO2020004945A2 (es) 2020-05-05
EP3700913A1 (en) 2020-09-02
CL2020001076A1 (es) 2021-02-19
ECSP20023056A (es) 2020-12-31
PE20210394A1 (es) 2021-03-02
JOP20200099A1 (ar) 2020-05-06
WO2019081292A1 (en) 2019-05-02
MX2020004191A (es) 2020-08-03
BR112020007983A2 (pt) 2020-10-27
JP2021500365A (ja) 2021-01-07
TW201932117A (zh) 2019-08-16
UA126456C2 (uk) 2022-10-05
LT3700913T (lt) 2022-01-25
MA50438A (fr) 2020-09-02
PT3700913T (pt) 2022-01-31
CY1124938T1 (el) 2023-01-05
AU2018356352A1 (en) 2020-04-16
PH12020550473A1 (en) 2021-03-08
UY37948A (es) 2019-05-31
HRP20220060T1 (hr) 2022-04-15
AR113791A1 (es) 2020-06-10
KR20200069361A (ko) 2020-06-16
CA3079767A1 (en) 2019-05-02
US20200338096A1 (en) 2020-10-29
HUE057278T2 (hu) 2022-04-28
NI202000030A (es) 2020-10-09
RS62984B1 (sr) 2022-03-31
DOP2020000076A (es) 2020-08-31
MA50438B1 (fr) 2022-03-31
PL3700913T3 (pl) 2022-02-21
CR20200176A (es) 2020-07-24
EP3700913B1 (en) 2021-11-10
ES2906305T3 (es) 2022-04-18
SI3700913T1 (sl) 2022-02-28
SG11202003049WA (en) 2020-04-29
DK3700913T3 (da) 2022-02-07
EA202091025A1 (ru) 2020-07-30
CU24604B1 (es) 2022-06-06
US11298367B2 (en) 2022-04-12
IL273949A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
PE20190116A1 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
CL2014000384A1 (es) Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-2-alquinil/alquenil-etil)-1h-(1,2,4) triazol sustituidos; proceso para preparar dichos compuestos; composiciones agroquímicas.
PE20170945A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
HUP9901550A2 (hu) Növényimmunizáló hatású benzotiadiazolszármazékot tartalmazó szinergetikus fungicid készítmények és alkalmazásuk
EA201891396A1 (ru) Способ получения 2-[4-(4-хлорфенокси)-2-(трифторметил)фенил]-1-(1,2,4-триазол-1-ил)пропан-2-ола
CU24604B1 (es) Profármacos de derivados de triazol sustituido
PE20210859A1 (es) Inhibidores de triazol glicolato oxidasa
CL2020001624A1 (es) Cocristales de boscalida y triazoles.
AR102987A1 (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y compuesto(s) fungicida(s)
UY36964A (es) Combinaciones de principios activos que comprenden un derivado de (tio) carboxamida y un compuesto funguicida
MX2021011359A (es) Formulaciones estabilizadas de tiocetonas.
CO2018011948A2 (es) Procedimiento para la preparación de derivados de 1-fenilo-1,2,4- triazol sustituidos por 5-hidroxialquilo
MA46077A1 (fr) Composés et mélanges fongicides pour la lutte contre les maladies fongiques dans des céréales
EA201492032A1 (ru) Способ получения соединений триазола
PE20091719A1 (es) Composiciones fungicidas con 3&#39;-bromo-2,3,4,6&#39;-tetrametoxi-2&#39;,6-dimetilbenzofenona
NZ599070A (en) Heterobicycle-substituted azolyl benzene fungicides
AR035220A1 (es) Mezclas fungicidas.
AR056488A1 (es) FORMULACIONES FUNGICIDAS DE TRIAZOL LíQUIDAS CONCENTRADAS
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
PY1639431A (es) Combinaciones fungicidas y su uso para la protección de cultivos
MX2023002804A (es) Un proceso para la preparación de compuesto de triazol.
EA201792319A1 (ru) Полиморфы триазолонового соединения, ингибирующего pges-1
ES2328328A1 (es) Polimorfo alfa de una pirazolina sustituida, su preparacion y su uso como medicamento
GB201600330D0 (en) Fluconazole medicine intermediate 2,4-dichloro-a-(1H-1,2,4- triazol-1-yl) acetophenone synthesis method